#United States #Cambridge #CREATE Medicines #Georg Schett #CRT-402

CREATE Medicines Expands Advisory Board to Propel Clinical Development

CREATE Medicines, Inc., an innovative biotechnology firm, is making significant strides in the realm of in vivo immune programming. Recently, the company announced the enlargement of its Clinical and Scientific Advisory Board with the notable appointments of Dr. Georg Schett, Dr. Margrit Wiesendanger, and Dr. Christopher Jewell. This strategic move aims to bolster the company’s initiatives particularly as they enhance the clinical development of CRT-402, an in vivo CD19 CAR-T program directed at treating B cell-driven autoimmune ailments.

Daniel Getts, the founder and CEO of CREATE Medicines, remarked on the appointment of these esteemed professionals, stating, “Georg, Margrit, and Chris are leaders who have shaped this area of science, with work spanning autoimmune disease, translational medicine, immunology, and next-generation therapeutic development. They join at exactly the moment our in vivo CAR-T platform is advancing in B cell-driven autoimmune disease.” The insights and expertise of these professionals are expected to be invaluable as CREATE pushes CRT-402 towards clinical applications and further develops its in vivo immune programming technology.

Dr. Georg Schett, one of the newly appointed members, serves as the Vice President of Research and Director of the Department of Medicine, Rheumatology and Immunology at Friedrich-Alexander-Universität Erlangen-Nürnberg. His previous work includes leading pioneering treatments for autoimmune conditions, which resulted in a breakthrough finding published in The New England Journal of Medicine, demonstrating the efficacy of ex vivo CAR-T therapy in refractory lupus patients. He is enthusiastic about the prospects of CREATE’s approach, emphasizing the need for accessible treatments for patients without the complexities associated with traditional methodologies.

Dr. Margrit Wiesendanger, a clinical rheumatologist at the Icahn School of Medicine at Mount Sinai, boasts an extensive background working with lupus patients combined with research specializing in B cell biology related to autoimmunity. Her academic credentials include a combined MD/PhD in Immunology, and she is board certified in both Rheumatology and Internal Medicine. Wiesendanger’s expertise will combine clinical and research insights, facilitating potential advancements in biological therapies tailored for systemic lupus erythematosus.

Contributing to CREATE’s advisory board is also Dr. Christopher Jewell, the Institute Professor of Translational Engineering at the University of Maryland, who has a rich history in guiding biotech innovations, especially in the realm of mRNA CAR-T therapies for autoimmune conditions. With over $40 million in funding backing his research and more than 150 patents to his name, Dr. Jewell is well-positioned to support CREATE in furthering its objectives within the competitive landscape of immunotherapy development.

CREATE Medicines is renowned for its pioneering approach in creating mRNA-LNP platforms, which directly engineer T cells, NK cells, and myeloid cells in-vivo, without the need for prior lab manipulation. This clinically-based technique enables the development of scalable, off-the-shelf immunotherapy solutions which are not only viable but also promise repeated therapeutic doses. Aside from CRT-402, CREATE is expanding its pipeline focusing on autoimmune diseases and cancer, showcasing its commitment to addressing pressing health challenges through innovative solutions.

With the enhanced strength of their advisory board, CREATE Medicines is set to make significant advancements in its clinical program, further paving the way for new prospects in the treatment of autoimmune diseases and improving the lives of patients affected by these conditions. The collaboration among these experienced leaders reaffirms the company's commitment to medical excellence and innovation, marking another critical step towards its goal of making effective therapies widely available to those in need.